Table 1.
Demographics, clinical presentation, and ancillary testing
| Median age (range), years | 65 (27–80) |
| Proportion male | 26/39 (67%) |
| Median serum LGI1‐IgG titer (range) | 640 (40–1280) |
| Median CSF LGI1‐IgG titer (range) | 5 (0–320) |
| Median serum VGKC value (range), nmol/L | 0.33 (0.14–4.63) |
| Median CSF VGKC value (range), nmol/L | 0.02 (0–0.4) |
| Manifestations | |
| Central nervous system | 37/39 (95%) |
| Seizures | 35/39 (90%) |
| Cognitive decline | 36/39 (92%) |
| Peripheral nervous system | 3/39 (8%) |
| Cancers diagnosed on follow‐up | 2/39 – 1 prostate and 1 ovary |
| Ancillary Testing | |
| Mesio‐temporal hyperintensity on MRI | 16/31 (52%) |
| Epileptic activity on EEG | 13/30 (43%) |
| Abnormal CSF | 23/33, 70% |
| Elevated protein | 22/33, 67% |
| Median protein (range), mg/dL | 56, (24–94) |
| Median WBC number (range) | 2 (0–55) |
| WBC > 5 | 6/39 (15%) |
| Oligoclonal IgG bands exceeding 4 | 3/27, 11% |